tiprankstipranks
Advertisement
Advertisement

HALO Stock Latest News

Halozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
RatingsHalozyme: Underappreciated, Durable Royalty-Driven Growth Beyond 2028 Supports Buy Rating
7h ago
HALO
Halozyme enters global global collaboration and license agreement with Vertex
PremiumThe Fly
Halozyme enters global global collaboration and license agreement with Vertex
2d ago
HALO
VRTX
Halozyme Names David Ramsay Interim Chief Financial Officer
PremiumCompany Announcements
Halozyme Names David Ramsay Interim Chief Financial Officer
28d ago
8K
HALO
Halozyme names David Ramsay as Interim CFO
PremiumThe Fly
Halozyme names David Ramsay as Interim CFO
28d ago
HALO
Halozyme price target raised to $94 from $78 at Morgan Stanley
PremiumThe Fly
Halozyme price target raised to $94 from $78 at Morgan Stanley
2M ago
HALO
Halozyme price target raised to $90 from $75 at Benchmark
PremiumThe FlyHalozyme price target raised to $90 from $75 at Benchmark
2M ago
HALO
Halozyme price target raised to $75 from $65 at Wells Fargo
Premium
The Fly
Halozyme price target raised to $75 from $65 at Wells Fargo
2M ago
HALO
Halozyme Earnings Call Highlights Royalty-Fueled Growth
Premium
Company Announcements
Halozyme Earnings Call Highlights Royalty-Fueled Growth
2M ago
HALO
Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
PremiumRatings
Halozyme: Strong Royalty Momentum and Underappreciated Multi‑Year Earnings Power Support Buy Rating
2M ago
HALO
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
PremiumThe Fly
Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18
2M ago
HALO
Halozyme reports Q4 EPS 24c vs. $1.26 last year
PremiumThe Fly
Halozyme reports Q4 EPS 24c vs. $1.26 last year
2M ago
HALO
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
PremiumThe Fly
Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B
2M ago
JNJ
GMAB
HALO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-EarningsHALO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
HALO
Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21
Premium
The Fly
Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21
2M ago
HALO
Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
Premium
The Fly
Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B
2M ago
HALO
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
PremiumThe Fly
Leerink views ‘major deal’ on Entyvio as positive for Halozyme
3M ago
TAK
HALO
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
PremiumRatings
Halozyme: ENHANZE Platform Partnerships in Immunology and Obesity Drive Underappreciated Royalty Upside and Support Buy Rating
3M ago
HALO
Halozyme price target raised to $90 from $79 at TD Cowen
PremiumThe Fly
Halozyme price target raised to $90 from $79 at TD Cowen
3M ago
HALO
Halozyme announces global collaboration, license agreement with Takeda
PremiumThe Fly
Halozyme announces global collaboration, license agreement with Takeda
3M ago
TAK
HALO
Halozyme price target lowered to $75 from $79 at Morgan Stanley
PremiumThe FlyHalozyme price target lowered to $75 from $79 at Morgan Stanley
3M ago
HALO
CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
Premium
The Fly
CoreWeave initiated, Shopify downgraded: Wall Street’s top analyst calls
3M ago
ACN
CVX
Skye Bioscience, Halozyme enter collaboration, license agreement
Premium
The Fly
Skye Bioscience, Halozyme enter collaboration, license agreement
3M ago
HALO
SKYE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >